Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-09

FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) from Gilead Sciences, Inc., resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)